




FIG. 1A




FIG. 1B




FIG. 1C




FIG. 1D



FIG. 2




FIG. 3A




FIG. 3B




FIG. 3C




FIG. 3D

10/175




FIG. 3E

11/175




FIG. 3F




FIG. 4A




FIG. 4B




FIG. 4C




FIG. 4D




FIG. 4E




FIG. 4F




FIG. 4G




FIG. 4H




FIG. 4I




FIG. 4J




FIG. 4K




FIG. 4L




FIG. 4M




FIG. 4N




FIG. 5A




FIG. 5B




FIG. 5C




FIG. 5D




FIG. 6A




FIG. 6B

32/175

SARS-CoV2 (MLV) neutralization




FIG. 7A

SARS-CoV2 (MLV) neutralization




FIG. 7B

33/175




FIG. 7C




FIG. 7D




FIG. 8A




FIG. 8B




FIG. 9A




FIG. 9B




FIG. 9C





FIG. 9D



	S2E12	S2E13	S2E11
IC50	10.827	30.755	81.350
IC80	21.436	61.400	88.180
IC90	31.966	92.005	92.438

FIG. 9E




FIG. 9F




FIG. 10A




FIG. 10B




FIG. 10C




FIG. 10D




FIG. 10E




FIG. 1IA




FIG. 11B




FIG. 11C




FIG. 1ID




FIG. 12A




FIG. 12B




FIG. 12C




FIG. 12D




FIG. 13A




FIG. 13B




FIG. 14A




FIG. 14B




FIG. 14C




FIG. 14D




FIG. 14E




FIG. 14F




FIG. 14G




FIG. 14H




FIG. 15

S2X127
S2X129
S2X132
S2X190
S2X193
S2X195
S2X244
S2X246
S2X256
S2X269
S2X278




FIG. 15 (Cont.)




FIG. 16A




FIG. 16B




FIG. 16C





FIG. 16D



	 S2M11	 S2M28
IC50	22.400	15.419
IC80	34.258	59.750
IC90	43.923	291.188

FIG. 17A





FIG. 17B



● S2M7 ▲ S2L49

IC50	69.261	76.997
IC80	149.209	216.429
IC90	235.261	423.369

FIG. 17C

S2M11




FIG. 18A




FIG. 18B




FIG. 18C




FIG. 18D




FIG. 18E




FIG. 19A




FIG. 19B




FIG. 19C




FIG. 19D




FIG. 19E




FIG. 20A




FIG. 20B




FIG. 21A




FIG. 21B




FIG. 22A




FIG. 22B




FIG. 23A





FIG. 23B

92/175



**complete with S309; bold underlined, cross-reactive to SARS1

FIG. 24




FIG. 25A




FIG. 25B




FIG. 26




FIG. 27

97/175




FIG. 28A

98/175




FIG. 28B




FIG. 29A




FIG. 29B




FIG. 30A




FIG. 30B

101/175




FIG. 31A

102/175




FIG. 31B




FIG. 32A




FIG. 32B




FIG. 32C

106/175




FIG. 33A




FIG. 33B

108/175




FIG. 34A

109/175




FIG. 34B

110/175




FIG. 35




FIG. 36

112/175




FIG. 37A

113/175




FIG. 37B

114/175




FIG. 38A

115/175




FIG. 38B




FIG. 39A




FIG. 39B




FIG. 40





FIG. 41

120/175

VSV-luc(SARS-CoV-2-spike) infection*FIG. 42*

121/175




FIG. 43

122/175




FIG. 44

123/175




FIG. 45




FIG. 46

125/175




FIG. 47

126/175




FIG. 48

127/175




FIG. 49

128/175




FIG. 50A




FIG. 50B




FIG. 51




FIG. 52




FIG. 53




FIG. 54

134/175




FIG. 55

135/175




FIG. 56A

136/175




FIG. 56B




FIG. 57




FIG. 58

138/175




FIG. 59




FIG. 60




FIG. 61

140/175




FIG. 62




FIG. 63

141/175




FIG. 64




FIG. 65




FIG. 66

143/175




FIG. 67




FIG. 68

145/175






FIG. 69

146/175

*FIG. 70*




FIG. 71




FIG. 72

149/175




FIG. 73

150/175




FIG. 74




FIG. 75





FIG. 76

153/175

*FIG. 77*

154/175




FIG. 78

155/175




FIG. 79




FIG. 80

157/175




FIG. 81




FIG. 82




FIG. 83




FIG. 84

Mechanism	Classes of antibodies				
	RBM (Ia-IIa)	RBM (Ib)	S2M11 Ib-lock	NTD	S309 (IV)
Fusogenic S rearrangement	++/+	-	-	-	-
ACE2 blockade	+	+	+	-	-
Fusion inhibition*	-	ND	+	ND	+
Effector functions**	-	+	+	++	++
Neut. on ACE2 ^{hi} cells	+	+	+	-	-
Neut. on ACE2 ^{lo} cells	+	+	+	+	+
Neut. on lectin enh. infection	+/-	ND	+	+	+
					Stem helix
					+
					++
					-
					+
					ND

FIG. 85




FIG. 86




FIG. 86 (Cont.)




FIG. 87

163/175




FIG. 88




FIG. 89




FIG. 90

166/175




FIG. 91




FIG. 92

168/175




FIG. 93

169/175




FIG. 94

170/175




FIG. 95

171/175




FIG. 96

172/175




FIG. 97




FIG. 98




FIG. 99

175/175

PK Parameter	C1501	C1502	C1503	Mean	SD	%CV
Time range for $T_{1/2}$ calculation	168-1512	168-1512	168-1512	--	--	--
C_{max} (ug/mL)	148	132	141	140	8.26	5.90
$T_{1/2}$ (h)	677	523	629	610	78.69	12.90
$T_{1/2}$ (day)	28.2	21.8	26.2	25.4	3.28	12.9
Vd_{ss} (mL/kg)	60.8	71.6	62.8	65.1	5.7	8.8
Vd_z (mL/kg)	62.4	72.7	64.5	66.6	5.4	8.1
Cl obs (mL/day/kg)	0.064	0.096	0.071	0.077	0.017	22.1
Cl pred (mL/day/kg)	0.064	0.098	0.071	0.078	0.018	23.1
T_{last} (day)	1512	1512	1512	1512	--	--
AUC_{0-last} (ug.day/mL)	61590	44496	57513	54530	8928	16.4
AUC_{0-inf} obs (ug.day/mL)	78184	51897	70310	66797	13491	20.2
AUC_{0-inf} pred (ug.day/mL)	77613	51239	70649	66500	13667	20.6
MRT_{0-last} (day)	537	490	541	522	28.41	5.4
MRT_{0-inf} (day)	951	743	883	859	105.96	12.3
λ_{z2} (1/day)	677	523	629	610	79	12.9
C_{max}/D (ug/mL/(mg/kg))	29.6	26.3	28.2	28.0	1.653	5.90
AUC_{0-last}/D (ug.day/mL/(mg/kg))	12318	8899	11503	10907	1785.6	16.4
AUC_{0-inf}/D (ug.day/mL/(mg/kg))	15637	10379	14062	13359	2698.2	20.2
AUC_{0-inf}/AUC_{0-last} (%)	1.27	1.17	1.22	1.22	0.05	4.10

FIG. 100